石明博士為和黃醫(yī)藥執(zhí)行副總裁、研發(fā)負責人兼首席醫(yī)學官。他負責帶領公司的藥物發(fā)現(xiàn)和臨床開發(fā)戰(zhàn)略和執(zhí)行。
于2022年加入和黃醫(yī)藥前，石博士曾任創(chuàng)勝集團的全球研發(fā)負責人兼首席醫(yī)學官，在中國和美國建立了一個強大的全球研發(fā)團隊，并將七個項目推進臨床開發(fā)及多項臨床前候選藥物提名。在此之前，石博士在諾華工作超過15 年，擔任過多個高級領導人員職位，包括全球項目臨床負責人，并在多個新型腫瘤/ 血液病產品的臨床開發(fā)中發(fā)揮了關鍵領導作用，包括從臨床概念驗證到成功執(zhí)行全球關鍵試驗、產品注冊和生命周期管理。
石博士擁有南加州大學分子藥理學和毒理學博士學位，并于哈佛大學醫(yī)學院進行博士后研究。他在北京協(xié)和醫(yī)學院完成其醫(yī)學學位。
Dr Michael Shi is the Executive Vice President, Head of R&D and Chief Medical Officer of HUTCHMED. He oversees the drug discovery and development of the company from strategy to execution.
Prior to joining HUTCHMED in 2022, Dr Shi was the Global Head of R&D and Chief Medical Officer at Transcenta Holding Limited where he helped build a strong global research and development organization across China and the U.S. and advanced seven programs into clinical development and multiple preclinical candidate nominations. Before that, Dr Shi worked at Novartis for over 15 years, where he held various senior leadership positions including global program clinical head in clinical development. He played key leadership roles in the clinical development of multiple novel oncology/hematology products from clinical proof-of-concept to successful execution of global pivotal trials, product registration and lifecycle management.?
Dr Shi holds a PhD in Molecular Pharmacology and Toxicology from the University of Southern California, and conducted postdoctoral research at the Harvard Medical School. He received his medical education from Peking Union Medical College.